Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aclaris Therapeutics filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer developing immuno-inflammatory disease candidates. The record includes 8-K disclosures for quarterly and annual financial results, Regulation FD presentations, clinical pipeline updates for ATI-052 and ATI-2138, and common stock sales under an amended and restated sales agreement.
Proxy materials describe board and shareholder voting matters, executive compensation, equity awards and governance procedures. The filings also identify ACRS common stock, Delaware incorporation, R&D spending, royalty revenue from Lilly and Sun Pharma license agreements and capital-structure disclosures tied to public equity financing.
Aclaris Therapeutics director Andrew N. Schiff reported routine equity compensation and an RSU vesting and conversion. On June 5, 2026, 11,580 restricted stock units vested and were converted into 11,580 shares of common stock, bringing his directly held common shares to 25,540.
On June 4, 2026, he received 10,987 new restricted stock units and a stock option for 42,350 shares at an exercise price of $4.71 per share, both granted under company equity plans. The option vests in twelve equal monthly installments starting July 4, 2026, and the new RSUs vest on June 4, 2027, subject to continuous service.
A separate indirect position of 434,455 common shares is held by Aisling Capital IV LP and related entities, over which Aisling GP, Aisling Partners, and their managers share voting and dispositive power. Dr. Schiff disclaims beneficial ownership of these Aisling-held shares except to the extent of his pecuniary interest.
Aclaris Therapeutics director Anand Mehra reported routine equity compensation activity. On June 4, 2026, he received 10,987 restricted stock units and a stock option for 42,350 shares of common stock at an exercise price of $4.71 per share, both granted at no cash cost.
The option vests in twelve equal monthly installments starting on July 4, 2026, while the 10,987 restricted stock units are scheduled to vest on June 4, 2027, subject to his continuous service. On June 5, 2026, 11,580 previously granted restricted stock units vested and were exercised into 11,580 shares of common stock, bringing his direct common stock holdings to 726,403 shares.
Humphries William D. reported acquisition or exercise transactions in this Form 4 filing.
Aclaris Therapeutics director William D. Humphries reported equity compensation activity. On June 4, 2026, he received grants of 10,987 restricted stock units and 42,350 stock options, each option exercisable at $4.71 per share. The RSUs vest in a single installment on June 4, 2027, and the options vest in twelve equal monthly installments starting July 4, 2026, subject to continuous service.
On June 5, 2026, 11,580 previously granted restricted stock units vested and were settled into 11,580 shares of common stock. Following these transactions, Humphries directly held 45,105 shares of Aclaris common stock, reflecting routine director compensation rather than open-market buying or selling.
Aclaris Therapeutics director Christopher P. Molineaux reported routine equity compensation activity. On June 4, 2026, he received 10,987 restricted stock units and 42,350 stock options with an exercise price of $4.71 per share. On June 5, 2026, 11,580 previously granted RSUs vested and converted into common stock, bringing his direct common share holdings to 69,536.
Aclaris Therapeutics director Vincent Milano reported equity compensation activity. On June 5, 2026, 11,580 restricted stock units vested and were settled into the same number of common shares, bringing his direct common stock holdings to 28,896 shares.
On June 4, 2026, he received 10,987 new restricted stock units that are scheduled to vest in one installment on June 4, 2027, and a grant of 42,350 stock options with a $4.71 exercise price, vesting in twelve equal monthly installments starting July 4, 2026, under Aclaris’s non-employee director compensation policy and 2025 Equity Incentive Plan.
Aclaris Therapeutics director Maxine Gowen reported equity compensation activity and an RSU vesting. On June 4, 2026, she received 10,987 Restricted Stock Units, each representing a right to one share of common stock, and a stock option for 42,350 shares at an exercise price of $4.71 per share. The option vests in twelve equal monthly installments starting July 4, 2026 under the company’s 2025 Equity Incentive Plan and non‑employee director compensation policy. On June 5, 2026, 11,580 RSUs vested and were converted into common stock at no cash cost, leaving Gowen with 33,334 common shares held directly. The filing shows awards and an RSU vesting, with no open‑market purchases or sales.
Aclaris Therapeutics, Inc. held its 2026 annual meeting of stockholders on June 4, 2026. Stockholders representing 112,499,671 shares, or approximately 80.55% of the 139,663,680 shares outstanding as of the record date, were present or represented by proxy, providing a strong quorum.
Two directors, Anand Mehra, M.D. and Maxine Gowen, Ph.D., were elected to serve until the 2029 annual meeting. An advisory vote approved the compensation of the company’s named executive officers. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Vivo Opportunity Fund entities report beneficial ownership stakes in Aclaris Therapeutics, Inc. Vivo Opportunity Fund Holdings, L.P. (via its general partner Vivo Opportunity, LLC) holds 5,966,370 shares of Common Stock, representing 4.3% of the class based on 139,663,680 shares outstanding as of April 30, 2026. Vivo Opportunity Cayman Fund, L.P. (via its general partner Vivo Opportunity Cayman, LLC) holds 700,296 shares, representing 0.5% of the class.
The filing is an Amendment No. 1 to a Schedule 13G/A and lists sole voting and dispositive power for each reporting entity over the stated shares. Signatures show transactions were certified by Kevin Dai as Managing Member on May 12, 2026.
Aclaris Therapeutics reported a larger quarterly loss as it ramped R&D on its immuno-inflammatory pipeline. For the three months ended March 31, 2026, revenue was $2.0 million, mainly from licensing and contract research, while net loss widened to $19.8 million from $15.1 million a year earlier.
Research and development expenses rose to $15.7 million, driven by ATI‑052 Phase 1 programs in atopic dermatitis and asthma, ATI‑9494 preclinical work, and broader discovery investments, partly offset by lower ATI‑2138 costs after a completed Phase 2a trial.
Aclaris strengthened its balance sheet by raising $57.9 million net through an at‑the‑market stock program, ending the quarter with $190.8 million in cash, cash equivalents and marketable securities and an accumulated deficit of $987.6 million. Management believes existing resources will fund operations for more than 12 months, while it continues to seek partnerships and potential royalty monetizations to support development of bosakitug, ATI‑052, ATI‑2138 and ATI‑9494.
Aclaris Therapeutics reported a larger net loss in the first quarter of 2026 as it increased investment in its immuno-inflammatory pipeline, while strengthening its cash position. Net loss was $19.8 million for the quarter, compared with $15.1 million a year earlier.
Total revenue was $2.0 million, up from $1.5 million, mainly from higher royalties under the Lilly and Sun Pharma license agreements. Research and development expenses rose to $15.7 million, driven by clinical work on ATI-052 and manufacturing costs for ATI-9494, partly offset by lower spending on ATI-2138.
In March 2026, Aclaris sold 18.4 million shares of common stock for gross proceeds of $59.8 million. Cash, cash equivalents and marketable securities were $190.8 million as of March 31, 2026, and the company believes this will fund operations through the end of 2028 while it advances programs including ATI-052, ATI-2138, bosakitug and ATI-9494.